Medicine & TechnologyA cancer drug by Johnson & Johnson and AbbVie called Imbruvica can significantly decrease risk of death and slow down disease advancement with an estimated 84 percent lowered risk.
After months of waiting and anticipation, the hepatitis C treatment price wars are finally getting under way. Express Scripts, the largest pharmacy benefits manager in the U.S., has released a new treatment from AbbVie as its exclusive treatment for patients with genotype 1, the most common form of the chronic disease. This drug covers 75% of the estimated 3.2 million Americans who are infected.
And this new drug will likely change the market for the hepatitis C treatments that are currently led by a pair of medications from Gilead Sciences which is likely to reach $20 billion in revenue next year thanks to demand for its treatments.